IRWD - Ironwood Pharmaceuticals Inc Stock Price, Fair Value and News

$4.53+0.05 (+1.12%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IRWD RSI Chart

IRWD Valuation

Market Cap

715.6M

Price/Earnings (Trailing)

77.68

Price/Sales (Trailing)

1.79

EV/EBITDA

Price/Free Cashflow

4.89

IRWD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IRWD Fundamentals

IRWD Revenue

Revenue (TTM)

400.6M

Rev. Growth (Yr)

-12.09%

Rev. Growth (Qtr)

26.07%

IRWD Earnings

Earnings (TTM)

9.2M

Earnings Growth (Yr)

99.92%

Earnings Growth (Qtr)

79.34%

IRWD Price Action

Last 7 days

9.8%

Last 30 days

3.7%

Last 90 days

-21.4%

Trailing 12 Months

-48.0%

IRWD Profitability

Operating Margin

95.23%

EBT Margin

21.50%

Return on Equity

-2.86%

Return on Assets

2.33%

Free Cashflow Yield

20.45%

IRWD Financial Health

Current Ratio

3.92

Debt/Equity

-0.62

Debt/Cashflow

0.74

IRWD Investor Care

Shares Dilution (1Y)

2.38%

Diluted EPS (TTM)

0.04

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	413.6M	400.6M	0	0
2023	417.1M	427.3M	432.4M	442.7M
2022	422.4M	415.6M	420.5M	410.6M
2021	398.4M	413.0M	413.3M	413.8M
2020	439.6M	426.8M	399.1M	389.5M
2019	343.0M	364.1M	436.0M	428.4M
2018	315.3M	331.3M	303.8M	343.4M
2017	260.1M	270.8M	291.5M	298.3M
2016	186.7M	213.3M	239.8M	274.0M
2015	90.8M	111.7M	134.3M	149.6M
2014	34.2M	31.4M	43.4M	76.4M
2013	118.4M	86.6M	54.7M	22.9M
2012	67.9M	71.2M	155.4M	150.2M
2011	45.3M	47.3M	50.5M	65.9M
2010	36.7M	39.1M	41.5M	43.9M
2009	0	0	0	34.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

CEO	Mr. Thomas A. McCourt
WEBSITE	ironwoodpharma.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	219

Ironwood Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ironwood Pharmaceuticals Inc? What does IRWD stand for in stocks?

IRWD is the stock ticker symbol of Ironwood Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ironwood Pharmaceuticals Inc (IRWD)?

As of Tue Sep 17 2024, market cap of Ironwood Pharmaceuticals Inc is 715.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRWD stock?

You can check IRWD's fair value in chart for subscribers.

Is Ironwood Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IRWD is over valued or under valued. Whether Ironwood Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ironwood Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRWD.

What is Ironwood Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Sep 17 2024, IRWD's PE ratio (Price to Earnings) is 77.68 and Price to Sales (PS) ratio is 1.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRWD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ironwood Pharmaceuticals Inc's stock?

In the past 10 years, Ironwood Pharmaceuticals Inc has provided -0.082 (multiply by 100 for percentage) rate of return.